NEW YORK (GenomeWeb) – Protagen said today that it has granted a semi-exclusive license to San Diego-based Inova Diagnostics for its systemic sclerosis biomarker BICD2.

The license allows Inova to include BICD2 in its portfolio of connective tissue disease reagents aimed at aiding in the diagnosis of systemic sclerosis. Financial terms of the deal were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.